October 3, 2016
WEST TISBURY, Massachusetts
Radikal Therapeutics today announced that the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded the Company a $15.9 million for development of R-107, the first potential antidote to treat the life-threatening effects of chlorine inhalation, a potential terrorism threat. Today’s contract is part of efforts by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) to develop medical products and procedures to protect health and save lives in a terrorist attack, including those using toxic industrial chemicals like chlorine.
Chairman Andrew L. Salzman, M.D. noted that the HHS funding follows from strong preclinical data revealing potent activity of R-107, a novel bifunctional nitric oxide donor and redox degradation catalyst. The funding will support its advancement in manufacturing, pharmacology, and toxicology. If non-clinical studies are successful, R-107 could begin clinical studies to establish safety and efficacy in humans The contract could be extended up to a total of $84.9 million over seven years.
Further details can be found at http://www.hhs.gov/about/news/2016/09/29/bioterrorism-preparedness-hhs- sponsors-inhaled- chlorine-antidote.html
About Radikal Therapeutics (RTX)
RTX is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, the Company is positioned to remain at the forefront of drug discovery. RTX’s team of chemists, biologists, immunologists, and drug development professionals has worked together for more than two decades and has built a reputation for leadership in basic science and drug development. The Company is developing best-in- class therapeutics in a range of clinical areas, including inflammation, ischemia-reperfusion injury, and auto-immunity. The product platforms include small and large molecule pharmaceuticals that therapeutically restore free radical equilibrium, redirect aberrant signaling pathways in inflammation, manipulate mitochondrial cell death pathways, modulate DNA repair, restore microcirculatory perfusion, and induce specific immunotolerance. Although varied in their structural targets and directed at diverse clinical needs, the Company’s technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents.
Andrew L. Salzman, M.D.
1-866- 925-2871 x.709